XVIVO Perfusion (XVIVO) 44th Annual J.P. Morgan Healthcare Conference summary

Vision and Market Need

• Only 10% of the global transplant need is met annually, with 1.7–2 million needing transplants but only 170,000 performed in 2024.

• Utilization rates for organs in the US remain low: lungs at 20%, hearts at 27%, kidneys and livers at 64%.

• Key challenge is underutilization of donated organs, not just donor shortages.

• Donor demographics are shifting to older and DCD donors, increasing organ quality uncertainty.

• Market growth is driven by expanding donor pools and improved organ utilization, with transplant volumes expected to grow exponentially.

Technology, Product Portfolio, and Offerings

• Offers technologies and services for organ recovery, preservation, and machine perfusion for all major organs.

• Product portfolio includes gold-standard solutions for lung, heart, liver, and kidney, as well as organ recovery and perfusion services.

• Only company developing and commercializing perfusates for transplantation.

• Heart technology is the most innovative, pending approval in Europe and the U.S.

• Expanded from lung preservation to a full thoracic and abdominal portfolio, including market-leading technologies for kidney and liver.

Market Position and Financials

• Recognized as a global leader in all-organ transplantation, with a strong presence in the Americas and EMEA.

• Main revenue currently from lung products; kidney and liver products approved in select markets.

• Holds global leadership in lung preservation and evaluation, and is the top provider in Europe for liver.

• Market split: 60% Americas, 35% EMEA, 5% APAC.

• Machine perfusion market potential is 10x larger than current standard of care, supporting high growth and profitability.